Q2-osavuosiraportti
35 päivää sitten‧33 min
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
250 000
Myynti
Määrä
20 295
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 17 500 | - | - | ||
| 4 761 | - | - | ||
| 18 518 | - | - | ||
| 1 000 | - | - | ||
| 2 000 | - | - |
Ylin
0,138VWAP
Alin
0,134VaihtoMäärä
0 44 179
VWAP
Ylin
0,138Alin
0,134VaihtoMäärä
0 44 179
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 44 179 | 44 179 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 44 179 | 44 179 | 0 | 0 |
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 14.8. | |
| 2024 Yhtiökokous | 16.4. | |
| 2024 Q4-osavuosiraportti | 20.3. | |
| 2024 Q3-osavuosiraportti | 15.11.2024 | |
| 2024 Q3-osavuosiraportti | 14.11.2024 |
Datan lähde: Millistream, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
1 päivä sitten·It's also a bit strange - that when you try to buy, Nordea settles you at a rate of 0.1355 and the trade doesn't go through the market. I wonder why :)- 1 päivä sitten·The seeping trend continues. And now suddenly 2,000,000 shares are on offer. They're probably the ones who've been selling lately. Strange behavior - maybe you should sell before them ;)
- 11.9.·I think there are some who are taking a little profit here. I have to say - both did well! but there was nothing really big in the bag beyond what was already known. So it makes sense that the stock is leaking a little and I think it will continue until we hear news about Portinho or a partner agreement. (Portinho, itself was not a topic yesterday) but when you brought it up anyway, I think you could be more specific about deadlines or measures in relation to Portinho "advanced negotiations" are difficult to relate to when it is quite significant in terms of funding and valuation.11.9.·so, if you are looking for a well-located hotel plot in Madeira, it is cheaper to buy the entire PEG at today's market value :D ....
- 9.9.·So tomorrow we'll hear from the 2 CEOs... it'll be exciting to see if they have anything good up their sleeve :)
9.9.·I look forward to hearing what the new study means for commercialization opportunities. Are licensing partners already (extra) interested now because of the approval? Or do you wait until the study is paid for and completed, so that perhaps an even better deal can be negotiated in the event of equally strong results? - 3.9.·New event from PEG on the heels of the Phase 2 study approval - they've just started doing the right thing!: Meet and ask Reponex CEO Sebastian Bo Jakobsen and Pharma Equity Group CEO Christian Tange on Wednesday, September 10th at 10:30 AM. Following the regulatory approval for the Phase 2 study with RNX-011 (life-threatening peritonitis), Reponex CEO Sebastian Bo Jakobsen will review the next phase of the study and what the approval entails. In addition, Pharma Equity Group CEO Christian Tange will review the commercialization opportunities for RNX-011 Pharma Equity Group's portfolio company, Reponex, focuses on repositioning existing APIs (active pharmaceutical ingredients) for new indications. Reponex has a large portfolio of Phase 2 projects in the following disease areas: – Bacterial peritonitis – Chronic skin ulcers – Inflammatory bowel diseases – Colorectal cancer The company works with a partnership-based model and aims to commercialize the projects after completing Phase 2.3.9.·Yes - it's a funny time to want to get rid of your shares. Now something is finally happening on the clinical front, and then you want to get out? Of course, there may be some who don't have much faith in the future, but if you've been in the stock for a long time, it's a funny time to sell NOW.3.9.·If it were mine - I would have at least NOT sold at the moment and certainly not at a price of 0.155 or 0.30 ... But, there may also be other reasons why one should sell one's shares. It may also be that the market maker knows the interest and shows it in the market. And is waiting for a call from an investor with slightly deeper pockets for the risk.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Q2-osavuosiraportti
35 päivää sitten‧33 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 1 päivä sitten·It's also a bit strange - that when you try to buy, Nordea settles you at a rate of 0.1355 and the trade doesn't go through the market. I wonder why :)
- 1 päivä sitten·The seeping trend continues. And now suddenly 2,000,000 shares are on offer. They're probably the ones who've been selling lately. Strange behavior - maybe you should sell before them ;)
- 11.9.·I think there are some who are taking a little profit here. I have to say - both did well! but there was nothing really big in the bag beyond what was already known. So it makes sense that the stock is leaking a little and I think it will continue until we hear news about Portinho or a partner agreement. (Portinho, itself was not a topic yesterday) but when you brought it up anyway, I think you could be more specific about deadlines or measures in relation to Portinho "advanced negotiations" are difficult to relate to when it is quite significant in terms of funding and valuation.11.9.·so, if you are looking for a well-located hotel plot in Madeira, it is cheaper to buy the entire PEG at today's market value :D ....
- 9.9.·So tomorrow we'll hear from the 2 CEOs... it'll be exciting to see if they have anything good up their sleeve :)9.9.·I look forward to hearing what the new study means for commercialization opportunities. Are licensing partners already (extra) interested now because of the approval? Or do you wait until the study is paid for and completed, so that perhaps an even better deal can be negotiated in the event of equally strong results?
- 3.9.·New event from PEG on the heels of the Phase 2 study approval - they've just started doing the right thing!: Meet and ask Reponex CEO Sebastian Bo Jakobsen and Pharma Equity Group CEO Christian Tange on Wednesday, September 10th at 10:30 AM. Following the regulatory approval for the Phase 2 study with RNX-011 (life-threatening peritonitis), Reponex CEO Sebastian Bo Jakobsen will review the next phase of the study and what the approval entails. In addition, Pharma Equity Group CEO Christian Tange will review the commercialization opportunities for RNX-011 Pharma Equity Group's portfolio company, Reponex, focuses on repositioning existing APIs (active pharmaceutical ingredients) for new indications. Reponex has a large portfolio of Phase 2 projects in the following disease areas: – Bacterial peritonitis – Chronic skin ulcers – Inflammatory bowel diseases – Colorectal cancer The company works with a partnership-based model and aims to commercialize the projects after completing Phase 2.3.9.·Yes - it's a funny time to want to get rid of your shares. Now something is finally happening on the clinical front, and then you want to get out? Of course, there may be some who don't have much faith in the future, but if you've been in the stock for a long time, it's a funny time to sell NOW.3.9.·If it were mine - I would have at least NOT sold at the moment and certainly not at a price of 0.155 or 0.30 ... But, there may also be other reasons why one should sell one's shares. It may also be that the market maker knows the interest and shows it in the market. And is waiting for a call from an investor with slightly deeper pockets for the risk.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
250 000
Myynti
Määrä
20 295
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 17 500 | - | - | ||
| 4 761 | - | - | ||
| 18 518 | - | - | ||
| 1 000 | - | - | ||
| 2 000 | - | - |
Ylin
0,138VWAP
Alin
0,134VaihtoMäärä
0 44 179
VWAP
Ylin
0,138Alin
0,134VaihtoMäärä
0 44 179
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 44 179 | 44 179 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 44 179 | 44 179 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 14.8. | |
| 2024 Yhtiökokous | 16.4. | |
| 2024 Q4-osavuosiraportti | 20.3. | |
| 2024 Q3-osavuosiraportti | 15.11.2024 | |
| 2024 Q3-osavuosiraportti | 14.11.2024 |
Datan lähde: Millistream, Quartr
Q2-osavuosiraportti
35 päivää sitten‧33 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 14.8. | |
| 2024 Yhtiökokous | 16.4. | |
| 2024 Q4-osavuosiraportti | 20.3. | |
| 2024 Q3-osavuosiraportti | 15.11.2024 | |
| 2024 Q3-osavuosiraportti | 14.11.2024 |
Datan lähde: Millistream, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 1 päivä sitten·It's also a bit strange - that when you try to buy, Nordea settles you at a rate of 0.1355 and the trade doesn't go through the market. I wonder why :)
- 1 päivä sitten·The seeping trend continues. And now suddenly 2,000,000 shares are on offer. They're probably the ones who've been selling lately. Strange behavior - maybe you should sell before them ;)
- 11.9.·I think there are some who are taking a little profit here. I have to say - both did well! but there was nothing really big in the bag beyond what was already known. So it makes sense that the stock is leaking a little and I think it will continue until we hear news about Portinho or a partner agreement. (Portinho, itself was not a topic yesterday) but when you brought it up anyway, I think you could be more specific about deadlines or measures in relation to Portinho "advanced negotiations" are difficult to relate to when it is quite significant in terms of funding and valuation.11.9.·so, if you are looking for a well-located hotel plot in Madeira, it is cheaper to buy the entire PEG at today's market value :D ....
- 9.9.·So tomorrow we'll hear from the 2 CEOs... it'll be exciting to see if they have anything good up their sleeve :)9.9.·I look forward to hearing what the new study means for commercialization opportunities. Are licensing partners already (extra) interested now because of the approval? Or do you wait until the study is paid for and completed, so that perhaps an even better deal can be negotiated in the event of equally strong results?
- 3.9.·New event from PEG on the heels of the Phase 2 study approval - they've just started doing the right thing!: Meet and ask Reponex CEO Sebastian Bo Jakobsen and Pharma Equity Group CEO Christian Tange on Wednesday, September 10th at 10:30 AM. Following the regulatory approval for the Phase 2 study with RNX-011 (life-threatening peritonitis), Reponex CEO Sebastian Bo Jakobsen will review the next phase of the study and what the approval entails. In addition, Pharma Equity Group CEO Christian Tange will review the commercialization opportunities for RNX-011 Pharma Equity Group's portfolio company, Reponex, focuses on repositioning existing APIs (active pharmaceutical ingredients) for new indications. Reponex has a large portfolio of Phase 2 projects in the following disease areas: – Bacterial peritonitis – Chronic skin ulcers – Inflammatory bowel diseases – Colorectal cancer The company works with a partnership-based model and aims to commercialize the projects after completing Phase 2.3.9.·Yes - it's a funny time to want to get rid of your shares. Now something is finally happening on the clinical front, and then you want to get out? Of course, there may be some who don't have much faith in the future, but if you've been in the stock for a long time, it's a funny time to sell NOW.3.9.·If it were mine - I would have at least NOT sold at the moment and certainly not at a price of 0.155 or 0.30 ... But, there may also be other reasons why one should sell one's shares. It may also be that the market maker knows the interest and shows it in the market. And is waiting for a call from an investor with slightly deeper pockets for the risk.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
250 000
Myynti
Määrä
20 295
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 17 500 | - | - | ||
| 4 761 | - | - | ||
| 18 518 | - | - | ||
| 1 000 | - | - | ||
| 2 000 | - | - |
Ylin
0,138VWAP
Alin
0,134VaihtoMäärä
0 44 179
VWAP
Ylin
0,138Alin
0,134VaihtoMäärä
0 44 179
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 44 179 | 44 179 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 44 179 | 44 179 | 0 | 0 |